CVS Health: Big 2025 Momentum, Strong Growth Ahead, Shares Underpriced

  • CVS Health has shown impressive year-to-date performance, driven by strong Q1 results and strategic shifts in its business model. I reiterate a buy rating on CVS due to its low valuation, mixed technicals, and promising earnings growth prospects. Key catalysts include improved performance in Healthcare Benefits, higher star ratings in Medicare Advantage, and strategic exits from less profitable areas.